Status epilepticus refractory to first-line therapy is associated with a high morbidity and mortality. Correct diagnosis and adequate treatment of this condition require electrographic monitoring and anaesthetic facilities available in specialist intensive care units (ICUs) We carried out an audit of 26 patients admitted to a neurological ICU with a diagnosis of status epilepticus, to identify deficiencies in diagnosis and management prior to transfer to the ICU, and examine the effectiveness of ICU management. On transfer, only 14 (54%) were in status epilepticus; six were in drug-induced coma or were encephalopathic, and six had pseudostatus epilepticus, of whom four had been intubated. The commonest treatments prior to transfer were benzodiazepines, chlormethiazole and phenytoin; the loading dose of phenytoin was inadequate in at least 7/16 cases. All those in status epilepticus on transfer had their seizures successfully controlled, but ten required general anaesthesia with thiopentone, propofol, ketamine or midazolam. Two died-one had a severe encephalitis and the other had had a cardiac arrest prior to treatment. This study highlights deficiencies in the initial diagnosis and management of status epilepticus, the role of specialist neurological intensive care, and the importance of early referral.
Introduction
Status epilepticus (SE) is a clinical term referring to a condition characterized by an epileptic seizure or series of seizures without consciousness being regained that lasts for at least 30 min. Importantly, its definition is based solely upon the persistence of the seizure rather than its form, and the term thus covers all seizure types. 1 It is, however, convulsive SE that is of most importance, as it is associated with serious consequences, including focal neurological deficits, intellectual deterioration, chronic epilepsy and a high mortality. 1 Whether similar consequences occur with other types of SE is a matter of debate; in these cases morbidity and mortality are probably more closely associated with the underlying aetiology of the SE. Figures for the frequency of all types of SE are scant, but it has been estimated that the incidence in the UK alone (population of over 50 million) may be as high as 25 000 people per year, of which 9000-14 000 are convulsive SE. 2 The mortality for convulsive SE is dependent on the underlying aetiologies and the age of the patients, and thus varies from study to study; but even with modern management, it is probably of the order of 10%. 2 The mortality directly attributable to the consequences of the convulsive SE itself (i.e. not including deaths attributed to the underlying condition) has been estimated at 1-2 %. 2 This, however, does not take into account that the mortality of the underlying condition may substantially increase if SE occurs.
The first-line treatment of SE is effective in 70-80% of cases, but when this fails, the patient should be transferred to an intensive care unit (ICU) where intensive monitoring can take place, and where general anaesthesia can be given if necessary. 1 " 4 We have reviewed the patients admitted to a neurological ICU with a diagnosis of refractory SE in order to determine: (i) the type of SE, and the accuracy of previous diagnoses; (ii) why first-line therapy may have failed, and (iii) the effectiveness of the therapies that were instigated.
Methods
The National Hospital for Neurology and Neurosurgery (NHNN) is a tertiary referral centre and does not have a casualty department. The ICU accepts most of its referrals from other hospitals. We reviewed the records of 26 patients who had been transferred from other hospitals to our ICU with a diagnosis of intractable SE between 1 March 1993 and 31 October 1995. From the records, we determined the most likely diagnosis at time of admission to our ICU. The patients were divided into: those who were still in SE; those in whom SE had resolved, and in whom the electroencephalogram (EEC) and clinical findings were consistent with drug-induced coma (based on recovery from coma once the causative agent had been stopped); those in whom SE had resolved, and in whom the EEG and clinical findings were consistent with an encephalopathy; those who were likely to have had or were in pseudostatus epilepticus, and those who had a different diagnosis. As far as possible from the records, we determined the treatment in the referring hospital, and antiepileptic levels on arrival at our ICU before we had instigated any treatment. In those with a diagnosis of SE or probable SE, we identified the probable aetiology of the episode of SE. For all patients, we identified the treatments we instigated, the complications and the outcomes which were: discharge from NHNN; transfer back to the referring hospital conscious; transfer back to the referring hospital unconscious, and death.
Results

Patients and diagnosis
The median age was 33 years (17-73 years), and there were 15 men and 11 women. Eighteen had a previous history of epilepsy. Twelve patients (46%) were incorrectly diagnosed as having refractory status epilepticus. The diagnoses of the patients on admission to the ICU were: SE in 14; previous SE and drug-induced coma in four; previous SE, and encephalopathy in one; pseudostatus in six, and posthypoxic myoclonus in one (Table 1) . Of the 14 (54%) in SE, nine had convulsive SE, three had partial SE, one had tonic SE and one had non-convulsive SE.
The patients with pseudostatus tended to be younger than those who had or had had true SE (median age 21.5 vs. 34.0), and had a greater female to male ratio (4:2 vs. 7:12). A previous diagnosis of epilepsy was recorded for four patients (67%) with pseudostatus and 14 patients (73%) who had or had had true SE.
The aetiology of the SE in the 19 who had had or were in SE was unknown in six patients, and due to drug reduction or withdrawal in five, of which two were due to poor compliance. Other causes included: encephalitis, neurosarcoidosis, theophylline toxicity, neurocytoma, progressive myoclonic epilepsy, excess alcohol, lymphoma and cortical dysplasia.
Treatment prior to transfer
A range of treatments was used in the referring hospital prior to transfer ( Table 2) . Benzodiazepines (usually intermittent intravenous diazepam, although there were also instances of diazepam, clonazepam or midazolam infusions) were most frequently used followed by phenytoin and chlormethiazole. All four patients who were in drug-induced coma had had chlormethiazole, often in large doses (in one case over 10 I of 0.8% solution in 4 days). Rectal paraldehyde and phenobarbitone were occasionally used.
We were able to assess the loading dose of phenytoin in 16 cases; seven patients (44%) had not received an adequate loading dose ( < 7 5 0 mg), and four had possibly not received an adequate loading dose (750-1000 mg). Indeed, in two patients the loading dose for phenytoin was 200 mg or less. One of the two patients given phenobarbitone had not received an adequate loading dose.
AED serum concentrations were performed on transfer and before further treatment in 14 patients for phenytoin, and 8 cases for carbamazepine in patients supposedly receiving those AEDs. Six patients (43%) on phenytoin and four (50%) on carbamazepine fell below the lower limit of the therapeutic range for our laboratory (40 mmol/l for phenytoin and 20 mmol/l for carbamazepine). Overall the median levels and range were 47.5 mmol/l (12-96 mmol/l) for phenytoin and 24.5 mmol/l (0-43 mmol/l) for carbamazepine.
Only 50% of patients were intubated prior to transfer. A greater proportion of patients with pseudoseizures than patients with convulsive SE were intubated prior to transfer.
Treatment after transfer
Loading doses and adequate maintenance doses of AEDs were given as necessary. Patients in druginduced coma had their chlormethiazole stopped, were given adequate doses of AEDs and when necessary were weaned from their anaesthesia and extu bated.
Ten patients in SE required intubation and anaesthesia (Table 3) . Two patients in convulsive SE did not require anaesthesia. One patient, who had been given an inadequate loading dose of phenytoin, responded to a further bolus of phenytoin and one who had been treated with chlormethiazole alone responded to boluses of phenytoin and phenobarbitone. One patient with partial motor SE did not require anaesthesia, as he responded to a bolus of phenobarbitone (700 mg).
The commonest anaesthetic agent, used in seven patients, was propofol (1-10 mg/kg/h with 5 mg/kg/h usually being sufficient). Most patients responded well to whichever anaesthetic agent was chosen. In the case of non-convulsive SE, the patient was tried on thiopentone but this resulted in difficulties with hypotension, and so the patient was transferred on to propofol. In the case of partial motor SE due to cortical dysplasia, neither propofol nor thiopentone were able to control the seizures, and thus ketamine (100mg/h) was successfully used. This patient was eventually fully controlled following a subpial transection.
EEG monitoring was performed mostly using standard 10-20 system of scalp electrodes intermittently every 12-24 h. In three of the earlier cases of convulsive SE a cerebral function monitor was used. Burst suppression was only achieved in three patients and was achieved with propofol, thiopentone and midazolam. The attainment of burst suppression was not associated with a better outcome for those patients; indeed, two of them subsequently died. In most patients, adequate anaesthesia resulted in widespread slow activity with the abolishment of epileptic activity.
Complications
The commonest complication was chest infection which occurred in eight patients, all of whom had been ventilated (Table 4) . Four patients had cardiac arrests prior to admission to our ICU. Two of these had cardiac arrests during convulsive SE; in one this occurred in the ambulance on the way to the referring hospital before she had received any drug treatment, and the other had a cardiorespiratory 
arrest in the referring hospital following treatment with phenytoin, diazepam and then a chlormethiazole infusion. One patient had a cardiac arrest in the referring hospital prior to the episode of convulsive SE; this patient was an alcoholic who was also taking oral temazepam and chlormethiazole. One patient had a cardiac arrest in the referring hospital which resulted in post-hypoxic myoclonus. The cardiac arrests in these last two were antecedent to the status epilepticus, and were thus not included in Table 4 . One patient who had been in partial motor SE for 4 months and had been ventilated for a large part of this time, regained consciousness but developed a severe critical illness neuropathy.
Outcome
The eventual neurological outcome for all patients is unknown; of those transferred conscious, one had developed a left hemiplegia secondary to his neurosarcoidosis, and one was noted to have had a worsening of her pre-existing left pyramidal weakness. Twenty patients were either discharged or transferred back to the referring hospital conscious ( Table 5) . Two of the remaining four patients died at NHNN: one with non-convulsive SE and encephalitis died from renal failure, the other was the patient who, prior to admission to hospital, had a cardiac arrest-an event from which she never recovered.
The two patients who had antecedent cardiac arrests were unconscious on transfer back to the referring hospitals. In all cases, SE was successfully controlled.
Discussion
In this study, the diagnosis and management of SE prior to transfer to a neurological ICU were inadequate, and treatment of refractory SE in a specialist ICU resulted in a good outcome with few serious complications.
Inaccuracies in diagnosis
A high incidence of pseudostatus presenting as refractory SE has been previously reported, 5 but from our study it is also apparent that a large proportion of patients with a diagnosis of 'refractory SE' have pseudostatus. The inadequacy of diagnosis from most referring centres is partly due to lack of or insufficient EEG services available at those centres. As has been found in another study, 5 many patients with pseudostatus had a previous diagnosis of epilepsy which may have confounded the diagnosis. Pseudostatus is often misdiagnosed as true SE and is often refractory to initial therapy (leading to general anaesthesia and mechanical ventilation). 5 It is thus not only a dangerous misdiagnosis, but also a considerable drain on hospital facilities. It was common for admitting doctors in referring hospitals to fail to recognize the possibility of pseudostatus. Pseudostatus must be considered if an episode of SE does not respond promptly to adequate initial therapy, especially if the seizures are in any way atypical. Although in this and other studies, 5 there is a higher female to male ratio, it is important to note that pseudostatus can present in both sexes. A significant number of patients in this study were in drug-induced coma rather than SE. These referrals possibly result from a misunderstanding of the pharmacokinetics of benzodiazepines and chlormethiazole. Diazepam, for example, given acutely has a substantially shorter distribution half-life (approximately 1 h) than its elimination half-lives (approximately 30 h). 6 Thus, blood concentrations drop precipitously following a single bolus due to redistribution; infusions and repeat boluses, however, lead to accumulation and so persistent action resulting in prolonged coma. Chlormethiazole exhibits similar pharmacokinetics with extensive and rapid redistribution; the dose of the initial infusion can be titrated on a minute-to-minute basis according to seizure control without drug-induced coma. Because of this property, it is widely used in the UK. Infusions, however, can be complicated by hypotension, cardiac depression, respiratory arrest, rebound seizures, fluid overload and like benzodiazepines, this drug shows a marked propensity for dangerous accumulation with prolonged administration. 7 " 9 The prolonged use of chlormethiazole infusions cannot be recommended for these reasons; indeed, it has lost favour in recent reviews on the treatment of SE, 2 and is not available in the USA. In our study, one cardiorespiratory arrest prior to transfer probably resulted from a prolonged chlormethiazole infusion.
Management prior to transfer to ICU
In this study, the aetiology of the SE was AED reduction or withdrawal in 2 1 % of those who were still in SE. This is similar to other studies of SE. Reintroduction of a withdrawn AED often results in termination of the SE; however, in two patients this was not done at the referring hospital. The types of AED treatment (except the frequent use of chlormethiazole) at the referring hospital were otherwise those generally recommended by reviews on the subject.
1 ' 2 ' 12 The doses of AEDs given were, however, inadequate. Because of drug redistribution, large loading closes of AEDs have to be given in order to achieve rapid therapeutic blood levels. In the case of phenytoin, intravenous doses of 15-18 mg/kg ( > 1 0 0 0 mg for a 70 kg adult) should be given. 13 ' 14 Similarly, phenobarbitone should be given as an intravenous bolus of 10 mg/kg. 15 Phenobarbitone was seldom used in referring centres; phenobarbitone can be given rapidly, leads to rapid cessation of status in at least as many instances as phenytoin and diazepam, and is only rarely associated with respiratory depression (contrary to popular myth). 15 The inadequate loading doses and inadequate maintenance dose contributed to the generally subtherapeutic AED blood levels obtained on transfer to NHNN. The close monitoring of AED blood levels is mandatory in unconscious patients.
Many of these problems can be overcome by easily accessible protocols, and indeed it has been frequently found in studies of SE that the use of a protocol significantly improved the prognosis. 16 '
17
Treatment in the ICU
Following failure of initial treatment, early referral to an intensive care unit is mandatory, as the late stages of convulsive SE are associated with hyperthermia, acidosis, cardiac arrhythmias, hypotension, pulmonary oedema, hypoglycaemia, cerebral oedema, rhabdomyolysis, acute renal failure, hepatic compromise and disseminated intravascular coagulation. 18 " 21 Intubation and mechanical ventilation aid the treatment of many of these complications, and the use of general anaesthetic agents is an effective means of halting both motor and electrographic seizure activity.
The choice of anaesthesia in SE remains a matter of debate. The barbiturate anaesthetics (e.g. thiopentone) have the advantages of long experience in the treatment of status, putative cerebro-protective action and potent anti-epileptic activity. 22 ' 23 The main disadvantages, however, are in their pharmacokinetics. Thiopentone has saturable kinetics, with a resultant long half-life at high concentrations. It has a tendency to accumulate, and thus recovery times may be protracted in prolonged therapy; indeed it is not uncommon for a patient to remain comatose for days after the cessation of a relatively short thiopentone infusion. 24 It can result in hypotension, and concomitant inotropes are often required.
Propofol has more suitable kinetics, but less well documented anti-epileptic activity, and there has been only limited published experience of its use in SE. It is easy to use, fast-acting, and post-infusional recovery of consciousness is quick. There have been a number of favourable reports of its use in status, 25 " 27 and it has demonstrated some anti-epileptic activity in animal seizure models. 28 It has, however, been reported to precipitate seizures and SE, 29/ 30 and it has activated epileptiform discharges on the electrocorticogram in intraoperative recordings. 31 Further study is thus required before it can be routinely recommended for the treatment of SE. Benzodiazepine infusions can be used in anaesthetic doses, but suffer from unfavourable pharmacokinetics. Midazolam infusion is probably the safest, and there have been reports of its successful use in SE in adults and children. 32 " 34 To our knowledge, there have been no other reports of the successful use of ketamine in status epilepticus in humans.
Ketamine is a non-competitive inhibitor of N-methyl D-aspartate recepetors, and has been shown to have neuroprotective effects if given shortly after the initiation of status epilepticus, and to be useful in halting the late stages of status epilepticus in animal models. 35 ' 36 All the non-barbiturate anaesthetics carry a substantial risk of rebound seizures and recurrence of SE when they are withdrawn.
In summary, non-barbiturate anaesthetics have more favourable pharmacokinetics than barbiturate anaesthetics, but less definite anticonvulsant action. How important it is for an anaesthetic agent in SE to have intrinsic anticonvulsant activity has not been investigated, and thus which anaesthetic agent should be used remains uncertain; it is an area where good comparative trials are urgently required. We have, however, recently started to favour propofol in preference to thiopentone, because it easier to use, and in our experience is associated with less severe hypotension and a better outcome.
EEG monitoring of SE in the ICU
Once general anaesthesia is induced, electrographic monitoring is necessary, as a patient may enter a drug-induced coma with little outward sign of convulsions yet on-going electrographic epileptic activity. In addition^ if a patient is inadequately treated or has a severe underlying encephalopathy, then electromechanical disassociation may occur such that the patient enters a stage of subtle generalized convulsive SE characterized by profound coma, bilateral EEG ictal discharges and only subtle motor activity, regardless of the presence or absence of sedating drugs or paralysing agents. 37 ' 38 The electrographic end-point in the treatment of SE is controversial, however, as there are sparse published data on the subject. The titration of the dose of anaesthetic agents in SE is commonly based upon burst suppression on the EEG or cerebral function monitor (CFM) with interburst intervals of 2-30 s as an acceptable end-point. 16 ' 39 ' 40 Burst suppression supposedly represents disconnection of cerebral grey matter from underlying white matter. 41 In our experience, burst suppression was difficult to achieve, because the dose of anaesthesia required was not usually tolerated by the patient (leading in a number of patients to uncontrollable hypotension). We found that aiming for a more realistic end-point such as seizure suppression, although more difficult to define, was associated with a good outcome. Aiming for this also meant that careful anaesthetic titration with continuous EEG or cerebral function monitoring was often unnecessary, and indeed in most patients intermittent 12-24 hourly standard scalp EEG monitoring was sufficient.
Conclusions
Diagnosis of persistent SE in the referring hospital was often inaccurate with a large number of patients having pseudostatus-this was possibly due to inadequate EEG facilities and clinical failure to recognize this diagnostic possibility. The use of prolonged chlormethiazole infusions in the referring hospital resulted in persistent drug-related coma and, in one patient, cardiac arrest. AED treatment in the referring hospital frequently consisted of inadequate loading and maintenance doses, leading in some patients to subtherapeutic plasma AED concentrations. We would recommend the use of a standard protocol for treatment of SE such as is illustrated in Figure 1 , as this simple measure will undoubtedly improve its treatment. This study emphasizes both the advantages and the role of specialized intensive care units with access to neurological, medical, anaesthetic and neurophysiological expertise in the accurate diagnosis and treatment of refractory SE. Despite this, there is at present little scientific basis for the choice of drug treatments in intractable SE. Favourable case reports of the use of propofol in refractory SE have been borne out by our own experience, and propofol is now our anaesthetic agent of choice. There continues, however, to be a need for good comparative trials in the treatment of refractory SE.
